Glycorex Transplantation Ab Class B · NGM:GTAB.B
Glycorex Transplantation Ab Class B — Stora Aktiedagen Stockholm 2020
17 slides from Glycorex Transplantation Ab Class B's conference presentation, Dec 2, 2020
Slide 1: Stora Aktiedagen Stockholm 2020
Stora Aktiedagen Stockholm 2020 2 december 2020 Pontus Nobréus, CEO
Slide 2: Global burden of kidney failure – a major and rising problem
Global burden of kidney failure – a major and rising problem Nature reviews Nephrology, volume 16, Oct 2020 The current and future landscape of dialysis
Slide 3: Kidney failure – large impact on the individual and the society
Kidney failure – large impact on the individual and the society Challenging situation in the US: • More than 37 millions with chronic kidney disease • >726,000 Americans need dialysis or kidney transplants to survive • >500,000 receive dialysis three times a week • >100,000 on waiting list for kidne
Slide 4: Challenges with access to kidney transplantations
Challenges with access to kidney transplantations Gap between supply and demand ABO incompatible blood groups O A B AB Advancing American Kidney Health U.S. Department of Health and Human Services
Slide 5: Innovative technology for safe and efficient ABO-incompatible transplantations
Innovative technology for safe and efficient ABO-incompatible transplantations Anti-A/B IgG & IgM antibodies Plasma O Proteins A B Antibodies Glycosorb® ABO AB Specific removal of Anti-A/B antibodies without effect on other antibodies or plasma components
Slide 6: Glycosorb® ABO compatible with standard plasma separation systems
apheresis. Glycosorb®-ABO is compatible with a wide range of plasma separators, both centrifugation BOEmMUSBUJPOFRVJQNFOU5IFEVSBUJPOPGBUSFBUNFOUTFTTJPOVTVBMMZSBOHFTCFUXFFOIPVSTBOE EFQFOETPOUIFTJ[FPGUIFQBUJFOU UIFQMBTNBnPXSBUFBOEUIFUPUBMOVNCFSPGUSFBUFEQMBTNBWPMVNFT As in other extracorporeal procedur
Slide 7: In clinical use for 19 years > 50 publications
In clinical use for 19 years > 50 publications 4,500 transplantations 190 centers in 28 countries
Slide 8: Strong clinical long-term evidence
Strong clinical long-term evidence 100 90 ABO-compatible, N=2909 80 70 ABO-incompatible, N=555 60 50 40 30 20 10 2 4 6 8 10 12 11-year uncensored graft survival (2005-2016) as reported by Scandiatransplant http://www.scandiatransplant.org:8080/Scandiatransplant/members/nkg/Scandia17.ppt/view
Slide 9: Global transplantations trends
Global transplantations trends 160 000 120 000 140 000 100 000 120 000 80 000 100 000 80 000 60 000 60 000 40 000 40 000 20 000 20 000 0 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Kidney Liver Heart Lung Pancreas Small bowel Kideny DD Kidney
Slide 10: Top 25 countries Living Donor Kidney transplantations 2019
Top 25 countries Living Donor Kidney transplantations 2019 10 000 9 000 8 000 7 000 6 000 5 000 4 000 3 000 2 000 1 000 0 l y an ia o ria m a A ey a n ic s ina ly ea da n ce en bia il bia ain ae nd an ali pa in ic US az tio d bl do Ita an d ge or rk na ed Is r ex Ch In nt lom ra Sp rla Br str pu rm
Slide 11: Glycosorb® ABO - large market potential Living Donor Kidney transplantations
Glycosorb® ABO - large market potential Living Donor Kidney transplantations Number of annual global Europe Kidney transplantations ~ SEK 80-120 million ~ 98 000 Annual Living donor Kidney India, Mexico & Turkey transplantations ~ SEK 125-185 million ~ 36 000 Estimated number of annual blood group i
Slide 12: Increasing number of blood group incompatible transplantations with Glycosorb® ABO
Increasing number of blood group incompatible transplantations with Glycosorb® ABO 25,0% Glycosorb® ABO 20,0% 15,0% 10,0% 5,0% Plasma exchange 0,0% 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Tyskland USA
Slide 13: Enable Universal Blood Plasma with Glycosorb® ABO – creating a new market
Enable Universal Blood Plasma with Glycosorb® ABO – creating a new market Plasma from donors of blood groups O, A & B AB AB A B A B 0 O Anti-A/B antibody reduced plasma Today’s practice for blood tranfusion After treatment with Glycosorb® ABO 4ml Estimated market for standardized blood plasma in EU:
Slide 14: Allogenic Hematopoietic Stem Cell Transplantation – large new application opportunity
Allogenic Hematopoietic Stem Cell Transplantation – large new application opportunity • Global market potential for Glycosorb® ABO ~ SEK 230 million • Large potential in Europe ~ SEK 100 million Dietger Niederwieser, et al., One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Disseminat
Slide 15: R&D Pipeline – focus on autoimmune diseases
R&D Pipeline – focus on autoimmune diseases Rheumatoid Artrit Other projects • 5 million people in EU • Myasthenia Gravis • No cure – immunosuppressive and anti- inflammatory drugs – up to 10% do not • Impact on muscle function respond • Typically treated with plasma exchange • Potential market in E
Slide 16: Summary – why invest in Glycorex Transplantation?
Summary – why invest in Glycorex Transplantation? • Glycosorb® ABO - clinical proven since 2001 addressing a large unmet need to increase transplantations and decrease waiting lists • Global market for Living Donor Kidney transplantations SEK 420 - 630 million • Strong position in Europe with furthe
Slide 17: TACK!
TACK!
Glycorex Transplantation — Stora Aktiedagen Stockholm 2020 on 6ix